Signatera™ Genome: the only genome-designed MRD assay with Medicare Coverage
Learn MoreSignatera™ Genome: the only genome-designed MRD assay with Medicare Coverage Learn More
Protect Health and Inform Earlier, More Targeted Interventions
Natera’s cell-free DNA tests help inform more personalized health care decisions.
Test
Measure fetal, tumor, or donor cfDNA at the molecular level with a noninvasive test.
Know
Identify risk of disease, detect recurrence, and understand treatment responses.
Decide
Make more-informed health decisions for individualized care.
Dedicated to Oncology, Women’s Health, and Organ Health
Oncology Tests
Characterize tumors, anticipate risk, and evaluate treatment response earlier than traditional tools. Hear Jeff’s story.
Women’s Health Tests
Identify risk of severe genetic conditions to help families prepare and inform early intervention that can improve outcomes. Hear Corrine’s story.
Organ Health Tests
Detect organ injury early and inform treatment strategy to improve transplant health. Hear Gigi’s story.
Innovating with Integrity
Innovating with Integrity
We participated in the largest prospective studies to date in molecular diagnostics in oncology (CIRCULATE), women’s health (SMART), and organ health (Trifecta). We meet or exceed applicable industry and regulatory standards for all of our tests to deliver high-quality results, and have processed over 10 million tests in our CAP/CLIA‑certified labs.
We have more than 150 medical professionals on staff who provide expert support to help make our test results clear and easy to understand.
Creating a World of Possibilities
Natera advances molecular diagnostics with integrity and scientific rigor, and supports integration of information provided by our tests into health care decision making.